Renal Anemia- Pipeline Insight, 2024

Renal Anemia- Pipeline Insight, 2024

DelveInsight’s, “Renal Anemia- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Renal Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Renal Anemia Understanding

Renal Anemia: Overview

Anemia of chronic renal disease, also known as anemia of chronic kidney disease (CKD), is a form of normocytic, normochromic, hypoproliferative anemia. Anemia is common in people with CKD, especially among people with more advanced kidney disease. Anemia in chronic renal disease is multifactorial. People with CKD who also have diabetes are at greater risk for anemia, tend to develop anemia earlier, and often have more severe anemia than people with CKD who don’t have diabetes. People older than 60 are also more likely to have anemia with CKD. Anemia related to CKD typically develops slowly and may cause few or no symptoms in early kidney disease. Symptoms of anemia in CKD may include: fatigue or tiredness, shortness of breath, unusually pale skin, weakness, body aches, chest pain and dizziness. Anemia in people with CKD often has more than one cause. The most common mechanism is Hypoproliferation due to decreased erythropoietin (EPO) production. Lack of EPO leads to loss of erythroferrone production, causing loss of hepcidin suppression and increased iron sequestration (as observed in the anemia of chronic disease). Treatment directs toward improving renal function (when possible) and measures aimed at increasing red blood cells production. ESAs, together with iron supplementation, is the treatment of choice in anemia of CKD. Anemia of renal disease is an independent risk factor for death. It has been shown to promote faster progression of left ventricular hypertrophy, peripheral oxygen demand and worsening of cardiac outcomes. More important anemia of renal failure leads to depression, fatigue, stroke, reduced exercise tolerance and increased rate of re-admissions. Long term treatment with erythropoietin can cause hypertension, vasoconstriction, and seizures. The management of the anemia of CKD is complex because it is not a simple matter of giving patients more blood transfusions or erythropoietin. Both these products have serious adverse effects when given chronically. One should never assume that anemia of renal disease is solely due to lack of erythropoietin, it may be due to poor nutrition or chronic illness- so a thorough workup is essential to determine the cause. Further, anemia of renal disease is also associated with adverse cardiac outcomes and hence the patient's cardiopulmonary status has to be monitored for life. Diagnosis of anemia of renal disease is based on demonstration of renal insufficiency, normocytic anemia, and peripheral reticulocytopenia.

""Renal Anemia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Renal Anemia pipeline landscape is provided which includes the disease overview and Renal Anemia treatment guidelines. The assessment part of the report embraces, in depth Renal Anemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Renal Anemia R&D. The therapies under development are focused on novel approaches to treat/improve Renal Anemia.

Renal Anemia Emerging Drugs Chapters

This segment of the Renal Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal Anemia Emerging Drugs

• HEC 53856: Sunshine Lake Pharma

HEC 53856, belongs to the class of antianaemics. HEC 53856 basically works as hypoxia-inducible factor-proline dioxygenase inhibitor. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Renal Anemia.

• AND 017: Kind Pharmaceuticals

AND 017, is an investigational compound .It belongs to the class of antianaemics. It works as Prolyl hydroxylase inhibitor. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Renal Anemia.

• DDO 3055: Jiangsu Hengrui Medicine Co.

DDO 3055 is an orally administered drug being developed by Jiangsu Hengrui Medicine, for the treatment of Renal Anemia. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Renal Anemia.

Further product details are provided in the report……..

Renal Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Renal Anemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Renal Anemia

There are approx. 20+ key companies which are developing the therapies for Renal Anemia. The companies which have their Renal Anemia drug candidates in the most advanced stage, i.e. Phase II include, Kind Pharmaceuticals.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Renal Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Renal Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal Anemia drugs.

Renal Anemia Report Insights

• Renal Anemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Renal Anemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Renal Anemia drugs?
• How many Renal Anemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal Anemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Renal Anemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal Anemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sunshine Lake Pharma
• Kind Pharmaceuticals
• Jiangsu Hengrui Medicine Co.
• Xiamen Amoytop Biotech
• Genexine Biologics
• Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
• Shenyang Sunshine Pharmaceutical Co., LTD.

Key Products

• HEC 53856
• AND 017
• DDO 3055
• YPEG-rhEPO
• efepoetin alfa
• RD01
• SSS17